Search clinical trials for: Mismatch-repair proficient

Total 32 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Bayer

Active, not recruiting

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Colon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer

United States
Jing-yuan Fang, MD, Ph. D

Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Colorectal Cancer

China
The Netherlands Cancer Institute
Agenus Inc.

Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

Resectable MMR-deficient Solid Tumors | Resectable MMR-proficient Solid Tumors

Netherlands
Yu jiren

Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Proficient Mismatch Repair

China
Baylor College of Medicine
Genentech, Inc.

Not yet recruiting

Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Stage I Colon Cancer | Stage II Colon Cancer | Stage III Colon Cancer

United States
Loyola University

Recruiting

Bridging the Health Disparities Gap in Decision-Making Among Limited English Proficient (LEP) Patients With Pelvic Floor Disorders

Preferred Level of Involvement in Decision Making LEP Patients

United States
Aston Sci. Inc.

Not yet recruiting

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone4)

Advanced Ovarian Cancer

United States
BeiGene

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

China, United States, Australia, Puerto Rico
Meril Life Sciences Pvt. Ltd.

Not yet recruiting

Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions (MeRethonRCT)

Coronary Artery Disease
Virginia Commonwealth University

Recruiting

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Endometrial Cancer | Recurrent Endometrial Cancer | Mismatch Repair-Proficient

United States
Zhejiang Cancer Hospital

Recruiting

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | Microsatellite Stable | Mismatch Repair-proficient

China
South West Sydney Local Health District

Recruiting

Capnodynamic Monitoring of Cardiorespiratory Function in Critically Ill Patients (PROFICIENT)

Sepsis | Acute Respiratory Infection | Postoperative Respiratory Distress

Australia
China Medical University, China

Recruiting

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Metastatic Colorectal Adenocarcinoma | MSS | pMMR

China
Asan Medical Center

Recruiting

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142)

Microsatellite Stable Colorectal Cancer | Mismatch Repair Proficient Colorectal Cancer | Microsatellite Unstable Colorectal Cancer | Mismatch Repair Deficient Colorectal Cancer

United States, Australia, Belgium, Canada, Ireland, Italy, Spain, France
Cancer Institute and Hospital, Chinese Academy...

Completed

Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

Gastric Cancer

China
University Health Network, Toronto
AstraZeneca

Active, not recruiting

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)

Pancreatic Adenocarcinoma | Leiomyosarcoma | Mismatch Repair Proficient Colorectal Cancer

Canada
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
Chandrikha Chandrasekharan
AstraZeneca; Biocompatibles UK Ltd

Suspended

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Rectal Cancer | Colon Cancer | Colorectal Cancer Metastatic | Liver Metastases | Colo-rectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Liver Metastasis Colon Cancer

United States
IFOM ETS - The AIRC Institute of Molecular Oncology

Active, not recruiting

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA)

Colorectal Neoplasms | Microsatellite Instability

Italy
Syndax Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Melanoma | Non-Small Cell Lung Cancer | Mismatch Repair-Proficient Colorectal Cancer

United States
Bayer
Bristol-Myers Squibb

Completed

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Colorectal Cancer

United States
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
Rottapharm Biotech
Agenus Inc.

Active, not recruiting

A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients

Solid Tumor | Metastatic Microsatellite-stable Colorectal Cancer | Mismatch Repair Protein Proficient | Refractory Metastatic Colorectal Cancer

Italy
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Withdrawn

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA... and other conditions

United States
University of Massachusetts, Worcester

Completed

Satisfaction of Limited English-Proficient Patients With Phone Interpretation Services Compared to In-Person Interpreters: A Randomized Controlled Trial (SIPI)

Pelvic Floor Disorders

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Withdrawn

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Colorectal Cancer
Daiichi Sankyo, Inc.
Bristol-Myers Squibb

Terminated

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Colorectal Neoplasm

United States
Children's Hospital Medical Center, Cincinnati

Completed

Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser

Use of the Belmont Rapid Infuser

United States
Mathematica Policy Research, Inc.
Robert Wood Johnson Foundation

Completed

Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)

Language Discordance

United States
Seattle Children's Hospital

Completed

Comparing Remote Interpreter Modalities in the Pediatric Emergency Department

Limited English Proficient Patients and Families

United States

Search clinical trials for: Mismatch-repair proficient

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations